SlideShare uma empresa Scribd logo
1 de 20
Managing costs in higher-income countries David Cameron University of Edinburgh
Economics
Is there anything more to be said?
France Highest per capita health care expenditure in Europe including €14 billion each year on cancer. Estimated annual GDP loss of €17 billion from cancer. ~ 20% of all cancer spend is on drugs
Cost of treatment ,[object Object],[object Object],[object Object],[object Object]
Cost of treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Cost of treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
European cancer drug spend ,[object Object]
Rising drug costs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Productivity is falling… Even allowing for inflation, industry is investing twice as much in R&D as it was a decade ago to produce two-fifths of the new medicines…..
Solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
New models ? Phase I. Many drugs………………………… Phase II. Fewer drugs…………… Phase III.  Few drugs Phase I. € Phase II. €€ Phase III. €€€€€€€€€€€€€€€ Market €€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ Phase I/II. Some drugs… Phase II/III smaller, less data Phase I/II. € Phase II/III. €€€€ Market €€€€€€€€€€€€€
Choice in spending
Choice in spending for society
So how to choose ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Lloyd A et al, British Journal of Cancer (2006) 95, 683 – 690
Price  ≠ Cost ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The future ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Make drug development  AND  drug use cost-effective

Mais conteúdo relacionado

Mais procurados

PillTime for Safer medicines
PillTime for Safer medicines PillTime for Safer medicines
PillTime for Safer medicines Paul Mayberry
 
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVEHIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVEiData Insights
 
How to monitor medicine prices
How to monitor medicine pricesHow to monitor medicine prices
How to monitor medicine pricesMeTApresents
 
9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)Cittadinanzattiva onlus
 
Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013Propane Studio
 
Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Office of Health Economics
 

Mais procurados (8)

Specialty one pager FINAL
Specialty one pager FINALSpecialty one pager FINAL
Specialty one pager FINAL
 
PillTime for Safer medicines
PillTime for Safer medicines PillTime for Safer medicines
PillTime for Safer medicines
 
Pharmacy Benefit Managers
Pharmacy Benefit ManagersPharmacy Benefit Managers
Pharmacy Benefit Managers
 
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVEHIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
HIGH COST OF CANCER DRUGS – PHARMA PERSPECTIVE
 
How to monitor medicine prices
How to monitor medicine pricesHow to monitor medicine prices
How to monitor medicine prices
 
9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)9th European Patients Rights Day - Kuiper (EFPIA)
9th European Patients Rights Day - Kuiper (EFPIA)
 
Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013Pharmaceutical Industry Analysis 2013
Pharmaceutical Industry Analysis 2013
 
Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?Multi-Indication Pricing: Do we want it? Can we operationalize it?
Multi-Indication Pricing: Do we want it? Can we operationalize it?
 

Semelhante a ABC1 - D.A. Cameron - Managing costs in higher-income countries

Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...Idia Ogala
 
Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27gilberto lopes
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in HealthcareSage Growth Partners
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019PhRMA
 
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew HillGSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew HillMakeMedicinesAffordable
 
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Canadian Organization for Rare Disorders
 
Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021Starttech Ventures
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018PhRMA
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018PhRMA
 
St. David's Prophylaxis Program
St. David's Prophylaxis ProgramSt. David's Prophylaxis Program
St. David's Prophylaxis ProgramSCBHealth
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019PhRMA
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019PhRMA
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018PhRMA
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
Pharmacoeconomics.ppt
Pharmacoeconomics.pptPharmacoeconomics.ppt
Pharmacoeconomics.pptPabitra Thapa
 

Semelhante a ABC1 - D.A. Cameron - Managing costs in higher-income countries (20)

The value of generics and biosimilar drugs
The value of generics and biosimilar drugsThe value of generics and biosimilar drugs
The value of generics and biosimilar drugs
 
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
Burroughs Wellcome - Retrovir Case Analysis (Idia Ogala - Lubin School of Bus...
 
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
Excessive prices in Pharmaceutical Markets - PARIS - OECD Competition Open Da...
 
A look at potential remedies for a broken system
A look at potential remedies for a broken systemA look at potential remedies for a broken system
A look at potential remedies for a broken system
 
Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27Access to cancer medications in low and middle income countries 2013.03.27
Access to cancer medications in low and middle income countries 2013.03.27
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in Healthcare
 
Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019Prescription Medicines - Costs in Context January 2019
Prescription Medicines - Costs in Context January 2019
 
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew HillGSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
GSIPA2M, Plenary 1, Return to Marrakech - Andrew Hill
 
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingWebinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
 
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
 
0403 1 Stefan Weber - approaches to value and pricing
0403 1 Stefan Weber - approaches to value and pricing0403 1 Stefan Weber - approaches to value and pricing
0403 1 Stefan Weber - approaches to value and pricing
 
Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021Clare Hague PhD, Pharma & Health Conference 2021
Clare Hague PhD, Pharma & Health Conference 2021
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
 
St. David's Prophylaxis Program
St. David's Prophylaxis ProgramSt. David's Prophylaxis Program
St. David's Prophylaxis Program
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019Prescription Medicines Costs in Context - June 2019
Prescription Medicines Costs in Context - June 2019
 
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
Pharmacoeconomics.ppt
Pharmacoeconomics.pptPharmacoeconomics.ppt
Pharmacoeconomics.ppt
 

Mais de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Mais de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Último

Lundin Gold - Q1 2024 Conference Call Presentation (Revised)
Lundin Gold - Q1 2024 Conference Call Presentation (Revised)Lundin Gold - Q1 2024 Conference Call Presentation (Revised)
Lundin Gold - Q1 2024 Conference Call Presentation (Revised)Adnet Communications
 
Power point presentation on enterprise performance management
Power point presentation on enterprise performance managementPower point presentation on enterprise performance management
Power point presentation on enterprise performance managementVaishnaviGunji
 
Structuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdfStructuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdflaloo_007
 
Falcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon investment
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel
 
Uneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration PresentationUneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration Presentationuneakwhite
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting
 
BeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfBeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfDerekIwanaka1
 
Falcon Invoice Discounting: Tailored Financial Wings
Falcon Invoice Discounting: Tailored Financial WingsFalcon Invoice Discounting: Tailored Financial Wings
Falcon Invoice Discounting: Tailored Financial WingsFalcon Invoice Discounting
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingNauman Safdar
 
Cracking the 'Career Pathing' Slideshare
Cracking the 'Career Pathing' SlideshareCracking the 'Career Pathing' Slideshare
Cracking the 'Career Pathing' SlideshareWorkforce Group
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptxRoofing Contractor
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxCynthia Clay
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSpanmisemningshen123
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...daisycvs
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon investment
 
Falcon Invoice Discounting: Aviate Your Cash Flow Challenges
Falcon Invoice Discounting: Aviate Your Cash Flow ChallengesFalcon Invoice Discounting: Aviate Your Cash Flow Challenges
Falcon Invoice Discounting: Aviate Your Cash Flow Challengeshemanthkumar470700
 

Último (20)

!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
 
Lundin Gold - Q1 2024 Conference Call Presentation (Revised)
Lundin Gold - Q1 2024 Conference Call Presentation (Revised)Lundin Gold - Q1 2024 Conference Call Presentation (Revised)
Lundin Gold - Q1 2024 Conference Call Presentation (Revised)
 
Power point presentation on enterprise performance management
Power point presentation on enterprise performance managementPower point presentation on enterprise performance management
Power point presentation on enterprise performance management
 
Structuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdfStructuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdf
 
Falcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business Growth
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
 
Uneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration PresentationUneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration Presentation
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investors
 
BeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfBeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdf
 
Buy gmail accounts.pdf buy Old Gmail Accounts
Buy gmail accounts.pdf buy Old Gmail AccountsBuy gmail accounts.pdf buy Old Gmail Accounts
Buy gmail accounts.pdf buy Old Gmail Accounts
 
Falcon Invoice Discounting: Tailored Financial Wings
Falcon Invoice Discounting: Tailored Financial WingsFalcon Invoice Discounting: Tailored Financial Wings
Falcon Invoice Discounting: Tailored Financial Wings
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
 
Cracking the 'Career Pathing' Slideshare
Cracking the 'Career Pathing' SlideshareCracking the 'Career Pathing' Slideshare
Cracking the 'Career Pathing' Slideshare
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptx
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business Potential
 
Falcon Invoice Discounting: Aviate Your Cash Flow Challenges
Falcon Invoice Discounting: Aviate Your Cash Flow ChallengesFalcon Invoice Discounting: Aviate Your Cash Flow Challenges
Falcon Invoice Discounting: Aviate Your Cash Flow Challenges
 
HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024
 

ABC1 - D.A. Cameron - Managing costs in higher-income countries

  • 1. Managing costs in higher-income countries David Cameron University of Edinburgh
  • 3. Is there anything more to be said?
  • 4. France Highest per capita health care expenditure in Europe including €14 billion each year on cancer. Estimated annual GDP loss of €17 billion from cancer. ~ 20% of all cancer spend is on drugs
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. Productivity is falling… Even allowing for inflation, industry is investing twice as much in R&D as it was a decade ago to produce two-fifths of the new medicines…..
  • 11.
  • 12. New models ? Phase I. Many drugs………………………… Phase II. Fewer drugs…………… Phase III. Few drugs Phase I. € Phase II. €€ Phase III. €€€€€€€€€€€€€€€ Market €€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€€ Phase I/II. Some drugs… Phase II/III smaller, less data Phase I/II. € Phase II/III. €€€€ Market €€€€€€€€€€€€€
  • 14. Choice in spending for society
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20. Make drug development AND drug use cost-effective

Notas do Editor

  1. This slide has presented many times before, showing that whilst R&D spending has continued to increase, the number of new medicines approved has declined, so productivity of pharma R&D is falling.